GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (LSE:AVCT) » Definitions » Earnings per Share (Diluted)

Avacta Group (LSE:AVCT) Earnings per Share (Diluted) : £-0.09 (TTM As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Avacta Group Earnings per Share (Diluted)?

Avacta Group's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was £-0.05. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.09.

Avacta Group's EPS (Basic) for the six months ended in Dec. 2023 was £-0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.09.

Avacta Group's EPS without NRI for the six months ended in Dec. 2023 was £-0.08. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.14.

During the past 3 years, the average EPS without NRIGrowth Rate was -24.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was -5.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was -13.60% per year.

During the past 13 years, Avacta Group's highest 3-Year average EPS without NRI Growth Rate was 79.70% per year. The lowest was -484.80% per year. And the median was -5.20% per year.


Avacta Group Earnings per Share (Diluted) Historical Data

The historical data trend for Avacta Group's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group Earnings per Share (Diluted) Chart

Avacta Group Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.14 -0.08 -0.11 -0.15 -0.09

Avacta Group Semi-Annual Data
Jul13 Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.03 -0.12 -0.04 -0.05

Competitive Comparison of Avacta Group's Earnings per Share (Diluted)

For the Biotechnology subindustry, Avacta Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avacta Group's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's PE Ratio distribution charts can be found below:

* The bar in red indicates where Avacta Group's PE Ratio falls into.



Avacta Group Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Avacta Group's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-24.947-0)/272.683
=-0.09

Avacta Group's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-13.415-0)/276.207
=-0.05

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Avacta Group  (LSE:AVCT) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Avacta Group Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Avacta Group's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Avacta Group (LSE:AVCT) Business Description

Industry
Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (LSE:AVCT) Headlines

No Headlines